论文部分内容阅读
目的研究恶性肿瘤患者红细胞ＣＲ１基因组密度多态性变化规律。方法采用ＰＣＲ和ＨｉｎｄⅢ酶切技术对恶性肿瘤红细胞ＣＲ１基因组密度多态性变化进行研究。结果１６４例恶性肿瘤患者红细胞ＣＲ１基因突变率４１．５％，明显高于１８９例正常人群（２１％），特别是年轻恶性肿瘤患者红细胞ＣＲ１基因点突变率可达６６．７％（２１例中），明显高于年轻正常人群（１９．８％，９６例）。在恶性肿瘤患者中红细胞ＣＲ１基因ＨＨ型的红细胞ＣＲ１活性高于红细胞ＣＲ１基因ＬＬ型患者，但低于正常人红细胞ＣＲ１活性。结论这些结果表明，红细胞ＣＲ１基因点突变率升高与免疫发病机理有相关性。
Objective To study the changes of erythrocyte CR1 genome density polymorphism in patients with malignant tumors. Methods PCR and HindIII digestion were used to study the changes of CR1 genomic density polymorphism in malignant erythrocytes. Results The chromosomal CR1 gene mutation rate was 41.5% in 164 patients with malignant tumors, which was significantly higher than that in 189 normal subjects (21%). In particular, the point mutation rate of erythrocyte CR1 gene in young patients with malignant tumors was 66.7% (21 cases). ), significantly higher than the young normal population (19.8%, 96 cases). The CR1 activity of erythrocyte CR1 gene HH in erythrocyte patients was higher than that of erythrocyte CR1 gene LL patients, but lower than that of normal human erythrocyte CR1 activity. Conclusion These results indicate that the elevated point mutation rate of CR1 in erythrocytes is related to the pathogenesis of the immune system.